Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis

The objective: to evaluate the effectiveness of the medication containing a 7% NaCl solution and 0.1% sodium hyaluronate in patients with destructive pulmonary tuberculosis and multiple/extensive drug resistance (MDR/XDR) and inflammatory changes in the tracheobronchial tree. Subjects and methods. A...

Full description

Saved in:
Bibliographic Details
Main Authors: E. P. Myshkova, S. V. Sklyuev, E. M. Zhukova, D. V. Krasnov, T. I. Petrenko
Format: Article
Language:Russian
Published: New Terra Publishing House 2020-08-01
Series:Туберкулез и болезни лёгких
Subjects:
Online Access:https://www.tibl-journal.com/jour/article/view/1441
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850282818468315136
author E. P. Myshkova
S. V. Sklyuev
E. M. Zhukova
D. V. Krasnov
T. I. Petrenko
author_facet E. P. Myshkova
S. V. Sklyuev
E. M. Zhukova
D. V. Krasnov
T. I. Petrenko
author_sort E. P. Myshkova
collection DOAJ
description The objective: to evaluate the effectiveness of the medication containing a 7% NaCl solution and 0.1% sodium hyaluronate in patients with destructive pulmonary tuberculosis and multiple/extensive drug resistance (MDR/XDR) and inflammatory changes in the tracheobronchial tree. Subjects and methods. A prospective randomized controlled study was carried out, which included 69 patients with destructive pulmonary tuberculosis and MDR/XDR and respiratory complaints and changes in the tracheobronchial tree detected by fibrobronchoscopy. All patients underwent a complete clinical and functional examination, and by analyzing the questionnaires, the mMRC dyspnea index was calculated, the CAT test was performed, and the response to treatment was assessed using the Likert scale. The patients were randomly divided into two groups. The main group included 30 patients; in addition to anti-tuberculosis therapy, through a nebulizer, they received inhalation with the solution containing 7% NaCl and 0.1% sodium hyaluronate, 5 ml 2 times a day for 10 consecutive days, 20 inhalations. The control group (39 people) received individual chemotherapy according to the resistance profile with standard mucolytic treatment. The examination was carried out before the course with the mucoactive drug (visit I), then at the end of the course – after 10 days (visit II) and after 30 days (visit III) from the moment of inclusion in the study. The significance of differences (p) was determined at p <0.05 using χ² Pearson, Fisher's exact test, Mann-Whitney test, and paired Wilcoxon test. Results. There was an increase in the effectiveness of treatment of patients in this category according to the following criteria: disappearance or decrease of respiratory symptoms (on the 10th day from the start of treatment), early regression of inflammatory changes in the tracheobronchial tree (on the 30th day from the start of treatment in 24 (73.4%) patients in the main group, in 10 (25.1%) patients in the comparison group (RR = 3.34; 95% CI 2.78-3.90)].
format Article
id doaj-art-e2f2eaa6f4d0413aa6e16d71219f5506
institution OA Journals
issn 2075-1230
2542-1506
language Russian
publishDate 2020-08-01
publisher New Terra Publishing House
record_format Article
series Туберкулез и болезни лёгких
spelling doaj-art-e2f2eaa6f4d0413aa6e16d71219f55062025-08-20T01:47:52ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062020-08-01987313610.21292/2075-1230-2020-98-7-31-361440Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosisE. P. Myshkova0S. V. Sklyuev1E. M. Zhukova2D. V. Krasnov3T. I. Petrenko4Novosibirsk Tuberculosis Research InstituteNovosibirsk Tuberculosis Research Institute; Novosibirsk State Medical UniversityNovosibirsk Tuberculosis Research InstituteNovosibirsk Tuberculosis Research Institute; Novosibirsk State Medical UniversityNovosibirsk Tuberculosis Research Institute; Novosibirsk State Medical UniversityThe objective: to evaluate the effectiveness of the medication containing a 7% NaCl solution and 0.1% sodium hyaluronate in patients with destructive pulmonary tuberculosis and multiple/extensive drug resistance (MDR/XDR) and inflammatory changes in the tracheobronchial tree. Subjects and methods. A prospective randomized controlled study was carried out, which included 69 patients with destructive pulmonary tuberculosis and MDR/XDR and respiratory complaints and changes in the tracheobronchial tree detected by fibrobronchoscopy. All patients underwent a complete clinical and functional examination, and by analyzing the questionnaires, the mMRC dyspnea index was calculated, the CAT test was performed, and the response to treatment was assessed using the Likert scale. The patients were randomly divided into two groups. The main group included 30 patients; in addition to anti-tuberculosis therapy, through a nebulizer, they received inhalation with the solution containing 7% NaCl and 0.1% sodium hyaluronate, 5 ml 2 times a day for 10 consecutive days, 20 inhalations. The control group (39 people) received individual chemotherapy according to the resistance profile with standard mucolytic treatment. The examination was carried out before the course with the mucoactive drug (visit I), then at the end of the course – after 10 days (visit II) and after 30 days (visit III) from the moment of inclusion in the study. The significance of differences (p) was determined at p <0.05 using χ² Pearson, Fisher's exact test, Mann-Whitney test, and paired Wilcoxon test. Results. There was an increase in the effectiveness of treatment of patients in this category according to the following criteria: disappearance or decrease of respiratory symptoms (on the 10th day from the start of treatment), early regression of inflammatory changes in the tracheobronchial tree (on the 30th day from the start of treatment in 24 (73.4%) patients in the main group, in 10 (25.1%) patients in the comparison group (RR = 3.34; 95% CI 2.78-3.90)].https://www.tibl-journal.com/jour/article/view/1441mucoactive therapydestructive pulmonary tuberculosis with mdr/xdrinflammation of the tracheobronchial tree
spellingShingle E. P. Myshkova
S. V. Sklyuev
E. M. Zhukova
D. V. Krasnov
T. I. Petrenko
Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
Туберкулез и болезни лёгких
mucoactive therapy
destructive pulmonary tuberculosis with mdr/xdr
inflammation of the tracheobronchial tree
title Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
title_full Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
title_fullStr Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
title_full_unstemmed Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
title_short Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
title_sort experience of using a combination mucoactive drug during chemotherapy in patients with mdr xdr tuberculosis
topic mucoactive therapy
destructive pulmonary tuberculosis with mdr/xdr
inflammation of the tracheobronchial tree
url https://www.tibl-journal.com/jour/article/view/1441
work_keys_str_mv AT epmyshkova experienceofusingacombinationmucoactivedrugduringchemotherapyinpatientswithmdrxdrtuberculosis
AT svsklyuev experienceofusingacombinationmucoactivedrugduringchemotherapyinpatientswithmdrxdrtuberculosis
AT emzhukova experienceofusingacombinationmucoactivedrugduringchemotherapyinpatientswithmdrxdrtuberculosis
AT dvkrasnov experienceofusingacombinationmucoactivedrugduringchemotherapyinpatientswithmdrxdrtuberculosis
AT tipetrenko experienceofusingacombinationmucoactivedrugduringchemotherapyinpatientswithmdrxdrtuberculosis